Reclaiming Your Foundation: A 10-Minute Guide to Rebuilding Leg Strength After 65 on September 9, 2026 Posted by
Beyond Metabolism: New Research Links GLP-1 Agonists to Reduced Respiratory Exacerbations on September 9, 2026 Posted by
The Perpetual Pursuit of Relief: Why Women Are Turning to Kratom and What It Reveals About Our Healthcare System on September 9, 2026 Posted by
A Legacy of Advocacy: The Alliance for Aging Research Releases 2025 Impact Report on September 9, 2026 Posted by
Philippines vs. Myanmar: A High-Stakes Tactical Showdown in the ASEAN Cup 2026 on September 9, 2026 Posted by
The Hidden Hazard: How Nighttime Light Pollution May Be Damaging Your Heart on September 9, 2026 Posted by
Global Tensions and Domestic Crises: A Comprehensive Review of Tuesday’s News on September 9, 2026 Posted by
Reclaiming Your Foundation: A 10-Minute Guide to Rebuilding Leg Strength After 65 on September 9, 2026 Posted by
Beyond Metabolism: New Research Links GLP-1 Agonists to Reduced Respiratory Exacerbations on September 9, 2026 Posted by
The Perpetual Pursuit of Relief: Why Women Are Turning to Kratom and What It Reveals About Our Healthcare System on September 9, 2026 Posted by
A Legacy of Advocacy: The Alliance for Aging Research Releases 2025 Impact Report on September 9, 2026 Posted by
Posted in Cardiovascular Recovery Early Intervention: Breakthrough Study Suggests PCSK9 Inhibitors Could Prevent First Heart Attacks in High-Risk Diabetes Patients on September 5, 2026
Posted in Medical Innovations The AMUNDSEN Trial: Does “Striking Early” with PCSK9 Inhibitors Improve Outcomes in Heart Attack Patients? on August 29, 2026
Posted in Cardiovascular Recovery Redefining Preventive Cardiology: New Study Shows PCSK9 Inhibitors Can Avert Cardiac Events in High-Risk Diabetic Patients on August 28, 2026
Posted in Cardiovascular Recovery Preventive Cardiology Breakthrough: PCSK9 Inhibitor Evolocumab Shows Promise for High-Risk Diabetes Patients on August 7, 2026
Posted in Cardiovascular Recovery Rethinking Heart Disease Prevention: Could Early PCSK9 Inhibition Transform Care for High-Risk Diabetes Patients? on July 30, 2026
Posted in Digital Health Tools A New Era in Cardiovascular Care: Merck’s Lipfendra Marks Historic Shift to Oral PCSK9 Inhibition on July 19, 2026
Posted in Medical Innovations A New Frontier in Cardiology: FDA Approves Lipfendra, the First Oral PCSK9 Inhibitor on July 17, 2026
Posted in Medical Innovations A New Era in Cardiology: FDA Greenlights Enlicitide, the First Oral PCSK9 Inhibitor on July 16, 2026
Posted in Cardiovascular Recovery Rethinking Prevention: New Study Suggests Earlier Intervention for High-Risk Diabetes Patients Using PCSK9 Inhibitors on July 14, 2026
Posted in Cardiovascular Recovery The VESALIUS-CV Trial: Exploring PCSK9 Inhibition in High-Risk Primary Prevention on May 10, 2026 rifanmuazin
